Exhibit
10.1


 


 





 


GenBio
Inc. Announces Filing of Provisional Patent Application for Its ImmuneResq{TM}


 


A
Nutraceutical Aimed at Treating Inflammation and the Chronic Serious Conditions that Result


 


ALISO
VIEJO, CA, UNITED STATES, April 12, 2022 /EINPresswire.com/ — GenBio, Inc. is pleased to announce it has filed a provisional
patent with the United States Patent Office (“USPTO”) and has (patent pending) status as of April 4th, 2022, on a new novel
natural extract demonstrating outstanding bioactivity in recent research. The company aims to identify molecular pathways to support
its nutraceutical developments called ImmuneResq{TM}


 


GenBio
has assembled an international research team to pursue, under the direction of the eminent scientific teams that undertook the original
pioneering research. Thirdly a specialist team from Oxfordshire, England will complement the research program. Genbio’s research
will be incorporated into the new range of FOMO Corp’s (OTC: FOMC) FOMO-brand drinks with the assistance of its strategic partner
Himalaya Technologies, Inc. (OTCMKTS:HMLA)


 


GenBio
holds the position that obesity is a chronic low-grade inflammation and that tackling the obesity epidemic head-on remains a top priority.
There is compelling evidence that the ‘Overfat’ pandemic, estimated to be 62-76% worldwide is comprised of individuals with
excess body fat sufficient to impair health. This overfat condition can also occur in significant numbers of normal-weight, non-obese
individuals. Being overfat increases the risk for a wide spectrum of common cardiovascular and metabolic abnormalities, chronic diseases,
physical impairment and can compromise the immune system.


 


The
aim of the research is also to focus on more efficient ways of reducing inflammatory cells and examine the role of cytokines, which are
an essential part of the body’s process to fight off diseases contracted, and injuries sustained as a normal part of living life.
The key research is to identify, then prevent, inflammatory cell penetration into the heart, liver and fat pads, even when individuals
continue a high fat diet. This will lead to prevention of the tissue damage caused by these excess inflammatory cells and prevent or
slow down the progression of the chronic disease without toxic side effects.


 


About
GenBio. Inc.


 



GenBio, Inc. (https://genbioinc.com/) A USA based biotechnology company aims to create, through its Investigative New Drug program
(IND), the next generation of anti-inflammatory drugs with the intention to disrupt the projected $191 billion+ anti-inflammatory drug
market. GenBio, in addition, has access to a vast catalog of natural herbs, extracts, superfoods and functional food ingredients that
can and will be formulated and licensed out to create a range of new nutraceuticals to aid in boosting the human immune system and promoting
good health and longevity.


 


About
Himalaya Technologies, Inc.


 


Himalaya
Technologies, Inc. (https://www.himalayatechnologies.com/) is a publicly traded company (OTCMKTS:HMLA). At the core it acquires
unique companies that drive shareholder value. HMLA invests and provides expansion capital for companies and technologies in multiple
sectors.


 


Forward
Looking Statements


 



Statements in this press release about the future expectations, including without limitation, the likelihood that GenBio, Inc. will be
able to meet minimum expectations, be successful and leverage capital markets to execute its growth strategy, constitute “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934,
and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties
and are subject to change at any time, and our actual results could differ materially from expected results. The Company undertakes no
obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of
this statement or to reflect the occurrence of unanticipated events, except as required by law. GenBio’s business strategy described
in this press release is subject to innumerable risks, most significantly, whether the Company is successful in securing adequate financing.
No information in this press release should be construed in any form, shape, or manner as an indication of the Company’s future
revenues or financial condition.


 


Contact:


Chief
Marketing Officer


 


Todd
D. Sonoga

GenBio Inc.

+1 949-705-8021

info@genbioinc.com